Gilteritinib as Bridging and Posttransplant Maintenance for Relapsed Acute Myeloid Leukemia with FLT3-ITD Mutation Accompanied by Extramedullary Disease in Elderly

Figure 2

Clinical course following treatment with gilteritinib. Cytogenetic abnormality by G-banding: 46, XX, t(1; 17)(p34; q21.2). CBT, cord blood transplantation; FluBuMel, fludarabine/busulfan/melphalan; PIR, pre-engraftment immune reaction; GVHD, graft-versus-host disease; WT1, Wilms’ tumor 1; FISH, fluorescence in situ hybridization.